AOD-9604 is a chopped-up piece of growth hormone (amino acids 176-191) designed to target fat without the rest of HGH's effects. Rats lost fat on it. Humans didn't. Metabolic Pharmaceuticals ran a real Phase 2b with 536 people and it flopped. No difference from placebo. They killed it in 2007. It's safe enough (no IGF-1 spike, no blood sugar issues), it just doesn't do anything. Now that sema and tirz exist, running AOD is like bringing a flip phone to a product launch.
AOD-9604 Protocol
Dose: 250-500mcg daily, taken fasted | Frequency: Once daily, morning on empty stomach | Cycle: 12-week cycles are common in the community. The clinical trial ran 24 weeks and still saw nothing. | Route: SubQ (abdominal injection, fasted)
This page exists because people still buy it. But the honest take is: it failed a properly powered human trial. If your goal is fat loss, look at the GLP-1 profiles instead.
AOD-9604 Effects
Fat metabolism (25%). Supposed to increase fat oxidation. Worked in rats. Didn't move the needle in humans.
Weight loss (15%). The Phase 2b trial result: no meaningful difference from placebo. That is the data.
No IGF-1 elevation (70%). One genuine positive: it does not raise IGF-1 or affect glucose. Safe, just not effective.
AOD-9604 Side Effects
Injection-site irritation (10%). Little red spot where you pinned. Goes away fast. Standard stuff.
Headache (5%). Occasional mild headache. Nothing to write home about.
Nausea (3%). Barely any gut effects, which tracks with the whole 'it doesn't really do much of anything' situation.
AOD-9604 Dosing by Use Case
Condition
Dose
Duration
Notes
Fat loss (claimed use)
250-500mcg SubQ daily, fasted
12 weeks
People still run this for fat loss. The Phase 2b trial with 536 obese adults showed no meaningful difference from placebo at 24 weeks. The rodent data was promising. The human data was not. GLP-1s now exist and produce 15-24% body weight loss in trials. This produces 0%.
Joint support (emerging angle)
250-500mcg SubQ daily
8-12 weeks
One animal study (Kwon et al. 2015) showed AOD-9604 injected into the joint improved rabbit osteoarthritis markers. This is extremely preliminary. Some clinics market it for joint health. The evidence is a single rabbit study.
If you insist on running it
250mcg SubQ daily, fasted, morning
12 weeks maximum
Inject fasted in the morning (same insulin logic as GH compounds). It is genuinely safe: no IGF-1 elevation, no blood sugar effects, no serious adverse events in the trial. It just didn't beat placebo for fat loss. If you want to try it as a low-risk experiment, 250mcg is the floor.
AOD-9604 Results Timeline
Week 1-4, Nothing measurable: No noticeable changes in body composition, energy, or appetite. This is consistent with the clinical trial data. Injection-site reactions are minimal.
Week 4-8, Still nothing measurable: The Phase 2b trial ran 24 weeks. At the halfway mark, the AOD group was not separating from placebo. If you're tracking body composition, don't expect movement attributable to this compound.
Week 8-12, Decision point: Twelve weeks is a reasonable experiment. If nothing has changed, that's consistent with the trial data. The honest recommendation: redirect your budget to a compound with proven human efficacy.
Frequently Asked Questions About AOD-9604
What is AOD-9604?
AOD-9604 is a synthetic fragment of human growth hormone, specifically amino acids 176-191. It was designed to isolate the fat-burning properties of HGH without the rest of its effects (no IGF-1 spike, no blood sugar impact). Rodent studies showed fat reduction. Metabolic Pharmaceuticals ran a Phase 2b trial with 536 obese adults. It didn't do what they designed it to do. They killed it in 2007.
Does AOD-9604 work for fat loss?
The Phase 2b trial says no. 536 participants, 24 weeks, randomized placebo-controlled. No statistically significant difference in weight loss between AOD-9604 and placebo. The rat data was promising. The human data was not. This is one of the few compounds where we have a properly powered human trial and it came back negative.
Is AOD-9604 safe?
Yes. That's the one genuinely positive finding. No IGF-1 elevation. No blood sugar effects. No serious adverse events in the trial. Minimal injection-site reactions. It's safe. It just doesn't do what it's marketed to do.
Why do people still buy AOD-9604?
Marketing and hope. It's cheaper than GLP-1s, doesn't require a prescription, and the "HGH fragment" branding sounds scientific. Vendors rarely mention the failed trial. If your goal is fat loss, semaglutide (15% weight loss in trials), tirzepatide (22.5%), or retatrutide (24.2%) all have published human data showing they actually work.
AOD-9604 vs semaglutide: which is better for fat loss?
Semaglutide, by a margin that isn't close. Semaglutide: 14.9% body weight loss in the STEP 1 trial (68 weeks, 1,961 participants). AOD-9604: no significant difference from placebo in a 536-person trial. The only advantage of AOD is cost and side effect profile: it's cheap and has almost no side effects. Because it doesn't do much of anything.
How do you reconstitute AOD-9604?
Add 2mL of bacteriostatic water to a 5mg vial. That gives you 2,500mcg per mL. For a 250mcg dose, draw 10 units on a U-100 insulin syringe. For 500mcg, draw 20 units. Inject subcutaneously in the abdomen on an empty stomach. Swirl gently. Never shake.
Evidence
Early research. The Phase 2b trial in 536 obese adults failed its primary endpoint for weight loss versus placebo at 24 weeks. Development was terminated in 2007. Rats got lean. Humans got nothing. The rats have not returned our calls for comment. In 2026, GLP-1 drugs exist and make AOD-9604 look like bringing a water pistol to a firefight.
Approval status: Failed clinical trials. Development discontinued 2007.
References
Ng FM et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone Horm Res, 2000. PMID 11146367
Heffernan MA et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment Int J Obes Relat Metab Disord, 2001. PMID 11673763
Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice Endocrinology, 2001. PMID 11713213
Cox HD et al. Detection and in vitro metabolism of AOD9604 Drug Test Anal, 2015. PMID 25208511
Kwon DR et al. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model Ann Clin Lab Sci, 2015. PMID 26275694
Storage
Lyophilized: Refrigerate 2-8C or freeze -20C for long-term. Standard peptide storage.
Reconstituted: Refrigerate at 2-8C. Use within 4-6 weeks. Do not freeze.
Water: Bacteriostatic water. 2mL per 5mg vial.
Needle: 30-31 gauge, 0.5 inch for SubQ
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
